Back to News & Events
Long Island Bioscience Hub Appoints Additional BioEntrepreneurs-In-Residence
August 22, 2018
Seasoned Industry Veterans Join Long Island Bioscience Hub’s BioEntrepreneur-in Residence Initiative
The Long Island Bioscience Hub, a collaboration between Stony Brook University, Brookhaven National Laboratory, Cold Spring Harbor Laboratory, and the Feinstein Institute at Northwell Health, announced the appointment of Dr. Boris Shor and Mr. Peter Young as its newest BioEntrepreneurs-In-Residence (BEIRs). Dr. Shor and Mr. Young have extensive bioscience industry experience affording them unique perspectives in the role of Bio Entrepreneur-in-Residence. Each will work with the Center for Biotechnology to identify commercially promising academic technologies that have the potential to support company formation.
Dr. Shor has nearly 15 years of experience in leading oncology programs and external R&D partnerships at the large pharmas and biotech companies, with specific focus on preclinical development of small molecule kinase inhibitors and biologics. Previously at Pfizer, Dr. Shor led internal and external collaboration project teams to develop novel antibody-drug conjugates and supported BLA filing for Inotuzumab, which was approved for the treatment of leukemia in 2017. Prior to that, he was a project team leader at the Oncology Unit of Wyeth, managing the discovery of novel kinase inhibitors for the treatment of cancer. He currently serves on the executive management team of early-stage biotech companies and is a founder of BioIDEA, a biotech pitch event in New York City. Dr. Shor received a Ph.D. in Molecular and Cell Biology at the State University of New York Downstate Medical Center and performed a postdoctoral fellowship in the Inflammation Research team at Johnson & Johnson Pharmaceutical R&D prior to joining Pfizer.
Mr. Young is an experienced life science industry consultant with over thirty-five years experience and currently serves as an executive-in-residence with Pappas Capital, where he leads the firm’s initiatives in translational research. He also serves on the Oversight Committee for the University of Miami Wallace H. Coulter Center for Translational Research and the Long Island Bioscience Hub External Review Board. He is a past member of the BIO board and chairman of NCBIO, the North Carolina industry trade association. Mr. Young earned a BA in History and an MBA from Indiana University.
“We couldn’t be more delighted to add Boris and Peter to the Center for Biotechnology’s roster of BioEntrepreneurs-in-Residence. The ongoing expansion of the BioEntrepreneur-in-Residence program is critical for the continued development of the bioscience industry in the region” Diane Fabel, Director of Operations at the Center for Biotechnology said. “The attraction and retention of skilled bioscience management talent is an important component of ensuring companies can be launched and also grow here.”
“I am thrilled to join the Center for Biotechnology as a BioEntrepreneur-in-Residence” Dr. Shor stated, “and I have already begun the work of assessing technologies and building a company. I appreciate the resources the Center for Biotechnology offers through their many programs not only to me, but to emerging companies throughout New York.”
“Having worked with the Center for Biotechnology as an advisor for several years, I am pleased to formally join the Center as BioEntrepreneur-in-Residence” Peter Young stated. “There is an incredible amount of activity related to bioscience development currently taking place right now in the region, and the Center’s many entrepreneurial programs provide a great springboard for significant industry expansion – I’m thrilled to be a part of it.”
In their roles as BEIRs, Dr. Shor and Mr. Young will work to identify a technology or technologies from within partner institutions that will create the foundation for licensing and company formation. They will have the support of the Center for Biotechnology business and technology development staff, as well as the support of external industry advisors to develop successful commercialization strategies. Ultimately, the goal is to help the company position itself prepare for SBIR/STTR grant opportunities, and Angel and VC investment.
Dr. Shor and Mr. Young join the eight BEIRs already working with the Center for Biotechnology who collectively have launched ten new companies in the last five years.
Related Stories
WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:50:15
[post_modified_gmt] => 2024-11-19 15:50:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 3464
[post_author] => 3
[post_date] => 2020-03-24 14:02:59
[post_date_gmt] => 2020-03-24 14:02:59
[post_content] => The Center for Biotechnology team is working remotely in order to continue our efforts to support our community. We are available to help clients with their technology and/or business development concerns, and are exploring ways in which we can provide services, programs, and events in a productive, socially responsible way.
We encourage you to stay in touch, and we provide updates to the community as things develop.
Stay well,
The Center for Biotechnology Team
[post_title] => Moving Forward
[post_excerpt] => During the time of the COVID-19 pandemic, the Center for Biotechnology team is working to support our community.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => moving-forward
[to_ping] =>
[pinged] =>
[post_modified] => 2020-03-24 15:50:04
[post_modified_gmt] => 2020-03-24 15:50:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3464
[menu_order] => 72
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 2689
[post_author] => 3
[post_date] => 2017-05-08 17:15:49
[post_date_gmt] => 2017-05-08 17:15:49
[post_content] => The Center for Biotechnology (CFB) at Stony Brook University is a New York State Center for Advanced Technology and the lead institution of the Long Island Bioscience Hub. The CFB provides the cross-institutional infrastructure for technology development, technology transfer, strategic industry partnerships, new company formation, attraction of investment capital, and other commercialization activities.
The CFB seeks ongoing technology and business development consulting services for its faculty and small business clients. The CFB works primarily with faculty and emerging small businesses to help them develop their technology and business strategy to prepare them for strategic partnerships and/or investment.
Consulting services anticipated, but not limited to:
- Conduct thorough due diligence on select technologies under consideration for investment by the CFB. Develop written assessments.
- Participate in in-person meetings on a weekly basis with faculty innovators and emerging companies to provide strategic guidance in intellectual property, competitive analysis, regulatory strategy, manufacturing, company formation and other issues related to commercialization strategies.
- Actively manage a project portfolio of funded technologies ensuring milestones are met and will add commercial value.
- Assist faculty in the development of applications for funding.
- Assist clients to develop effective fundraising strategies and materials.
- Participate in CFB technology and business development initiatives including the Boot Camp, Strategy Sessions, Long Island BioMentor Service and Life Sciences Summit.
- Help source and conduct due diligence on emerging company candidates for the Life Sciences Summit.
- Consult with CFB on specific technologies regarding commercialization and viability for moving forward.
- Consult with CFB clients on milestones required for licensing, strategic partnerships, investment, and/or manufacturing.
- Consult with CFB staff on client work, intellectual property, as well as patent, regulatory, commercialization strategies as needed.
- Consult on course content for CFB programs such as the Innovation Boot Camp and Fundamentals course. Serve as instructor or guest lecturer as needed.
- Review, interpretation, and advice of patents, websites, articles related to specific technology.
Required Qualifications:
- Direct experience in the management of business and technical issues associated with advanced bio-based technology commercialization, including:
- Due Diligence
- IP Strategy
- Fundraising
- Product development
- Regulatory
- Manufacturing (preferred)
- Sales and Marketing (preferred)
- Licensing
- Technology development experience in working with faculty-members and entrepreneurs seeking to commercialize early-stage technologies.
- Experience in technology development and initial IP landscape review and strategy development.
- Experience in the grant application review and the management of approved grants, including the identification and achievement of milestones that have material commercial value.
Progress Reports
Progress reports detailing meetings held/attended, project development issues, priorities, and other issues of importance are required on a monthly basis.
Time Commitment
- No less than one full day per week.
- Must be available to meet onsite and in-person with CFB staff and clients as needed and required by the CFB.
- Ability to respond to urgent requests and to fill in as needed is desirable.
Proposal Deadline
The CFB seeks proposals from qualified providers who have the expertise and desire to support the technology and business development objectives of the CFB. Interested parties should submit a proposal of no more than one page to Kristina Duryea at Kristina.Duryea@stonybrook.edu by 5p, May 26, 2017.
[post_title] => Request for Proposals: Technology & Business Development Services
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => request-for-proposals-technology-business-development-services
[to_ping] =>
[pinged] =>
[post_modified] => 2017-05-08 17:15:49
[post_modified_gmt] => 2017-05-08 17:15:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2689
[menu_order] => 147
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 3562
[post_author] => 3
[post_date] => 2020-06-17 10:53:38
[post_date_gmt] => 2020-06-17 10:53:38
[post_content] =>
https://fuzehub.com/cc-2020-info-session/
For more information on the competition or the Innovation Fund, visit the
Jeff Lawrence Innovation Fund.
[post_title] => Commercialization Competition: FuzeHub
[post_excerpt] => FuzeHub will be hosting a virtual info session ahead of its fourth New York State Commercialization Competition. Get all the details on applying for the competition at the July 7th information session.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => commercialization-competition-fuzehub
[to_ping] =>
[pinged] =>
[post_modified] => 2020-06-17 10:53:38
[post_modified_gmt] => 2020-06-17 10:53:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3562
[menu_order] => 65
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:50:15
[post_modified_gmt] => 2024-11-19 15:50:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 261
[max_num_pages] => 87
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
July 30, 2024
More Information
March 24, 2020
More Information
May 8, 2017
More Information
June 17, 2020
More Information